sorafenib has been researched along with lupeol in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (lupeol) | Trials (lupeol) | Recent Studies (post-2010) (lupeol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 466 | 0 | 266 |
| Protein | Taxonomy | sorafenib (IC50) | lupeol (IC50) |
|---|---|---|---|
| Cocaine esterase | Homo sapiens (human) | 1.9 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 2.12 | |
| Liver carboxylesterase 1 | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, K; Ansari, MA; Fatma, H; Jameel, M; Siddique, HR | 1 |
1 other study(ies) available for sorafenib and lupeol
| Article | Year |
|---|---|
Implication of Lupeol in compensating Sorafenib-induced perturbations of redox homeostasis: A preclinical study in mouse model.
Topics: Animals; Antioxidants; Apoptosis; Cytokines; Mice; Oxidation-Reduction; Oxidative Stress; Pentacyclic Triterpenes; Reactive Oxygen Species; Sorafenib | 2023 |